Search This Blog

Friday, September 14, 2018

Antioxidant NAC found to be effective in treating mice with osteoarthritis


Antioxidant found to be effective in treating mice with osteoarthritis
Antioxidant treatment with NAC prevented osteoarthritis and mitigated cartilage damage in the knee joints of mice deficient in Anp32 (right column). Credit: F.M.F. Cornelis et al., Science Translational Medicine (2018)
A team of researchers in Belgium and the Netherlands has found that feeding a common antioxidant to test mice was effective in treating osteoarthritis. In their paper published in Science Translational Medicine, the group outlines their study of the cause of the most prevalent joint disorder in the world and what they found.
Osteoarthritis is a degenerative disease that results in loss of joint cartilage and bone. It is most common in  and results in pain and disability for millions of people the world over. There is currently no cure and treatment is limited to drugs that reduce associated inflammation. In this new effort, the researchers have made inroads regarding understanding how the disease comes about and have found a therapy for it that proved effective in .
The work involved studying people experiencing . They studied tissue samples and found decreased levels of the protein ANP32A. So they investigated the role it plays in the body—genetic profiling showed that the protein was involved in monitoring levels of an enzyme called AMT. Under normal circumstances, levels were adjusted to respond to  in cells in joint cartilage—low levels led to increased stress. This finding suggested that boosting ANP32A levels artificially might prevent the progression of the disease. Intrigued by their findings, they administered an antioxidant called N-acetyl-cysteine (NAC) to test mice with osteoarthritis—they had been bred in a way that made them unable to make ANP32A. NAC is currently used to improve lung function in people with emphysema, cystic fibrosis, tuberculosis, bronchitis and other lung ailments. The researchers report that adding it to the mice’s water led to reduced loss of bone and cartilage compared to untreated mice.
The researchers note that because of differences in physiology, it is unlikely that giving NAC to people with osteoarthritis would help much—they plan instead to look for ways to induce increased production of ANP32A in patients, thereby preventing the  from taking its toll.
More information: Frederique M. F. Cornelis et al. ANP32A regulates ATM expression and prevents oxidative stress in cartilage, brain, and bone, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aar8426

Teva announces FDA OK of AJOVYTM injection for migraine prevention

Teva announced that the U.S. FDA has approved AJOVYTM injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly and monthly dosing options.
https://thefly.com/landingPageNews.php?id=2790937

#OpenAPS DIY Artificial Pancreas Tech Use Implies Improved A1C, Quality of Life


Patient-driven innovation in diabetes management has resulted in a group of people with type 1 diabetes who choose to build and share knowledge around a do-it-yourself (DIY) open source artificial pancreas systems (OpenAPS). The purpose of this study was to examine Twitter data to understand how patients, caregivers, and care partners perceive OpenAPS, the personal and emotional ramifications of using OpenAPS, and the influence of OpenAPS on daily life.
Qualitative netnography was used to analyze #OpenAPS on Twitter over a two-year period.
There were 328 patients, caregivers, and care partners who generated 3347 tweets. One overarching theme, OpenAPS changes lives, and five subthemes emerged from the data: (1) OpenAPS use suggests self-reported A1C and glucose variability improvement, (2) OpenAPS improves sense of diabetes burden and quality of life, (3) OpenAPS is perceived as safe, (4) patient/caregiver–provider interaction related to OpenAPS, and (5) technology adaptation for user needs.
As users of a patient-driven technology, OpenAPS users are self-reporting improved A1C, day-to-day glucose levels, and quality of life. Safety features important to individuals with diabetes are perceived to be embedded into OpenAPS technology. Twitter analysis provides insight on a patient population driving an innovative solution to improve their quality of diabetes care.

The Open Insulin Project: A Case Study for ‘Biohacked’ Medicines


New innovation ecosystems for drug discovery and development are emerging.
Members of the ‘do-it-yourself biology’ community, sometimes called ‘biohackers,’ are contributing to this new frontier by experimenting with the development of medical treatments and devices.
An initiative known as the Open Insulin Project is working to develop a protocol for insulin production in order to sidestep intellectual property.
Follow-on work could contribute to a number of different insulin distribution structures, including ‘home-brewed’ insulin for personal use.
The current regulatory system is incongruous with emerging innovation ecosystems such as the Open Insulin Project.
New innovation ecosystems are emerging that challenge the complex intellectual property and regulatory landscape surrounding drug development in the United States (US). A prime example is an initiative known as the Open Insulin Project. The goal of the project is to sidestep patents and enable generic manufacturers to produce cheaper insulin. However, the US regulatory environment, not patent exclusivity, is the main barrier to insulin affordability. If the Open Insulin Project succeeds in releasing an open protocol for insulin manufacturing, follow-on work could enable a number of new insulin production ecosystems, including ‘home-brewed’ insulin. Regulators will need to consider how to proceed in a future where commercial pharmaceuticals remain unaffordable, but patients are empowered to produce drugs for their personal use.

References

Abelson, R. and Thomas, K. (2018) Fed up with drug companies, hospitals decide to start their own. New York Times18 January 2018
  • Schellekens H.
  • et al.
Making individualized drugs a reality.
Nat. Biotechnol. 2017; 35507-513
  • Anon
Patient-centered drug manufacture.
Nat. Biotechnol. 2017; 35485
  • del Savio L.
The place of crowdfunding in the discovery of scientific and social value of medical research.
Bioethics. 2017; 31384-392
Smith, P.A. (2016) A do-it-yourself revolution in diabetes care, New York Times 23 February 2016
Zhang, S. (2018) A biohacker regrets publicly injecting himself with CRISPR. The Atlantic 20 February 2018
Lussenhop, J. (2017) Why I injected myself with an untested gene therapy. BBC News 21 November 2017
Nuffield Council on Bioethics (2017) Genome editing an ethical reviewa short guide. Nuffield Council on Bioethics
  • Hua X.
  • et al.
Expenditures and prices of antihyperglycemic medications in the United States: 2002–2013.
JAMA. 2016; 3151400
  • Greene J.A.
  • Riggs K.R.
Why is there no generic insulin? Historical origins of a modern problem.
N. Engl. J. Med. 2015; 3721171-1175
  • Beran D.
  • et al.
Constraints and challenges in access to insulin: a global perspective.
Lancet Diabetes Endocrinol. 2016; 4275-285
Thomas, K. (2017) Drug makers accused of fixing prices on insulin, New York Times 30 January 30, 2017
Picchi, A. (2018) The rising cost of insulin: “horror stories every day.” CBS News 9 May 2018
  • Cefalu W.T.
  • et al.
Insulin access and affordability working group: conclusions and recommendations.
Diabetes Care. 2018; 411299-1311
  • Muller N.
  • et al.
Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type 2 diabetes and human insulin.
Diabetes Care. 2013; 361865-1869
  • Davidson M.B.
Insulin analogs—is there a compelling case to use them?.
Diabetes Care. 2014; 371771-1774
  • Scott A.
  • et al.
Socioeconomic inequalities in mortality, morbidity, and diabetes management for adults with type 1 diabetes: a systematic review.
PLoS One. 2017; 12e0177210
  • Grintsova O.
  • et al.
Inequalities in health care among patients with type 2 diabetes by individual socio-economic status (SES) and regional deprivation: a systematic literature review.
Int. J. Equity Health. 2014; 1343
  • Heinemann L.
  • Hompesch M.
Biosimilar insulins.
J. Diabetes Sci. Technol. 2014; 86-13
  • Owens D.R.
  • et al.
The emergence of biosimilar insulin preparations—a cause for concern?.
Diabetes Technol. Ther. 2012; 14989-996
  • McCamish M.
  • Woollett G.
The state of the art in the development of biosimilars.
Clin. Pharmacol. Ther. 2012; 91405-417
  • Tsiftsoglou A.S.
  • et al.
Development and regulation of biosimilars: current status and future challenges.
BioDrugs. 2013; 27203-211
  • McCamish M.
  • Woollett G.
Worldwide experience with biosimilar development.
mAbs. 2011; 3209-217
  • Rotenstein L.S.
  • et al.
Opportunities and challenges for biosimilars: What’s on the horizon in the global insulin market?.
Clin. Diabetes. 2012; 30138-150
Ramsey, L. (2016) A cheaper version of the lifesaving diabetes medication just launched in the US, Business Insider 15 December 2016
  • Paradise J.
  • Janson C.
Decoding the research exemption.
Nat. Rev. Genet. 2006; 7148-154
  • Kaplan W.A.
  • Beall R.F.
The global intellectual property ecosystem for insulin and its public health implications: an observational study.
J. Pharm. Policy Pract. 2017; 103
  • Upadhyet S.
Understanding patent infringement under 35 U.S.C. 271(e): the collisions between patent, medical device and drug laws.
St. Clara High Technol. Law J. 2000; 177-8
  • Rathore A.S.
  • et al.
Monitoring quality of biotherapeutic products using multivariate data analysis.
AAPS J. 2016; 18793-800
  • Minghetti P.
  • et al.
Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
Health Policy (New York). 2014; 117328-333
  • Perez-Pinera P.
  • et al.
Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care.
Nat. Commun. 2016; 712211
  • Stark Casagrande S.
  • Cowie C.C.
Health insurance coverage among people with and without diabetes in the U.S. adult population.
Diabetes Care. 2012; 352243-2249

Jefferies Projects $573M Peak Sales For Cara Therapeutics’ Lead Candidate


Cara Therapeutics Inc CARA 1.63%, a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies.

The Analyst

Analyst Matthew Andrews initiated coverage of Cara with a Buy rating and $30 price target.

The Thesis

Cara’s lead program is intravenous Korsuva, which is being tested in chronic kidney disease on hemodialysis-associated pruritis, or CKD-HD-aP, Andrews said in the initiation note. (See his track record here.)
The drug has a promising opportunity given that 180,000 patients in the U.S. suffer from the disease and there is no FDA-approved drug, the analyst said.
Jefferies estimates peak penetration for Korsuva at 27 percent and peak-adjusted U.S. sales of $573 million.
The CR845 Phase 2/3 study for Korsuva met its primary endpoint by reducing the Worst Itch-Numeric Rating Scale, or WI-NRS, by 3.8 points at Week 8 from the baseline relative to a placebo, Andrew said.
Based on the data, the candidate was granted breakthrough therapy designation.
Andrews forecast a high likelihood of success in two similar Phase 3 U.S. and global studies initiated in January and December.
The top-line data from the Phase 3 studies, due in mid-2019, is likely to be Cara’s next key catalyst, the analyst said.
A Phase 2/3 study of IV CR845 showed statistically significant pain relief with reduced opioid-related side-effects in post-operative acute pain, according to Jefferies.